Senator Warren Says Powell Should Pause Rate Hikes, Remember Dual Mandate

-Bloomberg

byBenzinga Newsdesk

February 1, 2023

1 minute read

-Bloomberg

FDA
News

Cabaletta Bio Reports Clinical Data From 3rd Dose Cohort In DesCAARTes Trial In Patients With mPV

By Benzinga Newsdesk

Today, 9:59 PM

Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced

CABA

Dogecoin Co-Founder Has This To Say On His Expectations From Elon Musk As Twitter Board Member

By Samyuktha Sriram

Today, 9:59 PM

Billy Markus, co-creator of Dogecoin (CRYPTO: DOGE), doesn’t have any major expectations for DOGE following Elon Musk’s new seat on the Twitter Inc. (NYSE: TWTR) board.

$DOGE

Novavax’s COVID-19 Vaccine, Flu Shot Co-administration Preserved Efficacy, Likely ‘Viable Strategy,’ Company Says

By Vandana Singh

Today, 9:59 PM

Novavax Inc (NASDAQ:NVAX) announced its experimental COVID-19 vaccine remained effective when coadministered with an approved flu shot. Researchers are interested in…

NVAX

Belite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease Study

By Ragothaman Srinivasan

Today, 9:59 PM

Belite Bio (NASDAQ: BLTE) has initiated enrollment for the U.S. Phase 3 clinical trial of its lead asset LBS-008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment.

BLTE

Senator Warren Says Powell Should Pause Rate Hikes, Remember Dual Mandate

Related Posts

Cabaletta Bio Reports Clinical Data From 3rd Dose Cohort In DesCAARTes Trial In Patients With mPV

Dogecoin Co-Founder Has This To Say On His Expectations From Elon Musk As Twitter Board Member

Novavax’s COVID-19 Vaccine, Flu Shot Co-administration Preserved Efficacy, Likely ‘Viable Strategy,’ Company Says

Belite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease Study